The angiotensin II receptor type 2 polymorphism influences haemodynamic function and circulating RAS mediators in normotensive humans

被引:10
作者
Cherney, David Z. I. [1 ]
Lai, Vesta [1 ]
Miller, Judith A. [1 ]
Scholey, James W. [1 ]
Reich, Heather N. [1 ]
机构
[1] Univ Toronto ON, Div Nephrol, Toronto Gen Hosp, Toronto, ON, Canada
关键词
aldosterone escape; angiotensin II type 2 receptor gene polymorphism; renal haemodynamic function; renin-angiotensin-aldosterone system; GENE POLYMORPHISM; INHIBITION; SYSTEM; COMMON; STATE; G/A; AT1;
D O I
10.1093/ndt/gfq564
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background. The haemodynamic responses to angiotensin II type 1 (AT1) receptor blockade may be mediated in part by interactions between angiotensin II and the angiotensin II type 2 receptor (AT2R). An AT2R G1675A gene polymorphism has been described, but the functional effects of this polymorphism are unknown. Methods. Haemodynamic function, circulating renin-angiotensin system mediators and norepinephrine were measured in young healthy subjects at baseline and at 2 and 4 weeks after treatment with irbesartan. Subjects were divided into two groups on the basis of the AT2R G1675A gene polymorphism: GG subjects (n = 12) and AA/GA subjects (n = 22). Results. AA/AG subjects exhibited hypotensive and renal vasodilatory responses to irbesartan at 4 weeks, but GG subjects did not. In accord with haemodynamic effects, circulating aldosterone levels were suppressed in AA/AG, while circulating norepinephrine levels were augmented only in GG subjects. In contrast, increases in circulating renin, angiotensin II and plasma renin activity after irbesartan were exaggerated in AA/AG subjects. Conclusions. The AT2R G1675A polymorphism is a determinant of haemodynamic responses to AT1 receptor blockade, an effect that may be due to influences on aldosterone escape.
引用
收藏
页码:4093 / 4096
页数:4
相关论文
共 17 条
[11]   Relationship between diurnal blood pressure, renal hemodynamic function, and the renin-angiotensin system in type 1 diabetes [J].
Miller, JA ;
Curtis, JR ;
Sochett, EB .
DIABETES, 2003, 52 (07) :1806-1811
[12]   Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats [J].
Naruse, M ;
Tanabe, A ;
Sato, A ;
Takagi, S ;
Tsuchiya, K ;
Imaki, T ;
Takano, K .
HYPERTENSION, 2002, 40 (01) :28-33
[13]   Role of the angiotensin type 2 receptor gene in congenital anomalies of the kidney and urinary tract, CAKUT, of mice and men [J].
Nishimura, H ;
Yerkes, E ;
Hohenfellner, K ;
Miyazaki, Y ;
Ma, J ;
Hunley, TE ;
Yoshida, H ;
Ichiki, T ;
Threadgill, D ;
Phillips, JA ;
Hogan, BML ;
Fogo, A ;
Brock, JW ;
Inagami, T ;
Ichikawa, L .
MOLECULAR CELL, 1999, 3 (01) :1-10
[14]   Effect of the angiotensin II type 2-receptor gene (+1675 G/A) on left ventricular structure in humans [J].
Schmieder, RE ;
Erdmann, J ;
Delles, C ;
Jacobi, J ;
Fleck, E ;
Hilgers, K ;
Regitz-Zagrosek, V .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (01) :175-182
[15]  
SCHNURR E, 1980, CLIN NEPHROL, V13, P26
[16]   Impact of renin angiotensin system modulation on the hyperfiltration state in type 1 diabetes [J].
Sochett, Etienne B. ;
Cherney, David Z. I. ;
Curtis, Jacqueline R. ;
Dekker, Maria G. ;
Scholey, James W. ;
Miller, Judith A. .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 17 (06) :1703-1709
[17]   Intronic ANG II type 2 receptor gene polymorphism 1675 G/A modulates receptor protein expression but not mRNA splicing [J].
Warnecke, C ;
Mugrauer, P ;
Sürder, D ;
Erdmann, J ;
Schubert, C ;
Regitz-Zagrosek, V .
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 2005, 289 (06) :R1729-R1735